• miR-18a, ALOXE3, and Glioblastoma Ferroptosis

  2026-08-23

  Yang et al. identify a miR-18a/ALOXE3 axis that links ferroptosis resistance with increased glioblastoma migration and orthotopic tumor growth. The study provides a mechanistic framework for interpreting lipid-metabolism changes as coordinated regulators of cell survival and signaling rather than isolated molecular events.

• MMP-2 Liposomes for Sequential Immunotherapy

  2026-08-22

  The 2023 Acta Pharmaceutica Sinica B study developed an MMP-2-responsive, dual-targeting liposome that sequentially delivers the PD-1 pathway peptide AUNP-12 and the IDO inhibitor NLG919. Its cascade design links tumor-cell recognition, enzyme-triggered release, and immune-microenvironment remodeling in breast cancer models.

• Prevotella copri, IPA, and Breast Cancer Progression

  2026-08-21

  A 2024 Gut Microbes study identifies Prevotella copri as a microbiota-associated driver of breast cancer progression by consuming tryptophan and depleting host indole-3-pyruvic acid. The work links this metabolic change to UHRF1-mediated suppression of AMPK, providing a mechanistic framework for studying how gut microbial metabolism can alter tumor biology.

• Lisinopril Dihydrate for ACE Research

  2026-08-21

  Lisinopril dihydrate provides a practical, water-compatible route to controlled ACE inhibition in hypertension, heart failure, myocardial infarction, and renal disease workflows. This guide connects assay design with aminopeptidase selectivity controls, fresh-solution handling, dose optimization, and model-specific readouts.

• ST3GAL1 Drives F. nucleatum Adhesion in CRC

  2026-08-20

  The reference study identifies ST3GAL1-dependent sialylation as a host-cell determinant of Fusobacterium nucleatum adhesion to colorectal cancer cells. Its results connect altered surface glycosylation with persistent bacterial colonization through an H3K27ac/ANGPTL4 axis, providing a mechanistic framework for studying tumor-associated microbiota.

• Leupeptin: A Decision Framework for Protease Assays

  2026-08-20

  Leupeptin hemisulfate salt provides reversible, competitive control of serine and cysteine proteases. This evidence-focused guide connects assay design, autophagy and antiviral readouts with the orthogonal binding-validation logic of modern TET2 metabolite studies.

• Tolazoline: α2-Adrenergic Receptor Assay Guide

  2026-08-19

  Tolazoline helps researchers separate α2-adrenergic receptor signaling from downstream ATP-sensitive potassium channel effects in airway and islet models. This practical guide connects concentration selection, quantitative binding workflows, functional assays, and troubleshooting for more interpretable pharmacology.

• Methylprednisolone Sodium Succinate in Translation

  2026-08-19

  A mechanistic and translational framework for using Methylprednisolone Sodium Succinate in inflammation, immunology, tumor-cell apoptosis, and acute spinal cord injury research—while keeping experimental evidence distinct from clinical inference.

• AmpliFold Capture-and-Release Boosts LFA Sensitivity

  2026-08-18

  The AmpliFold strategy separates analyte capture from final signal development in a two-strip lateral flow assay, using cleavable linkers to collect complexes over a broad area before high-affinity rebinding at a narrow test line. In a HER2 model, this design produced up to 16-fold sensitivity enhancement and addressed kinetic limitations associated with low receptor density and large gold nanoparticles.

• D2HG Biosensors Reveal Metabolic STING Signaling

  2026-08-17

  Wang et al. developed genetically encoded D2HG biosensors by resolving how the bacterial regulator DhdR couples metabolite binding to DNA release. The resulting DHsers measure D2HG across a broad concentration range in living cells and identify elevated D2HG in cGAMP-stimulated macrophages, providing a practical bridge between metabolite imaging and innate immune signaling research.

• TET2 Metabolite Binding: Methods and Findings

  2026-08-16

  This 2025 STAR Protocols paper presents an integrated workflow that combines biochemical activity measurements with saturation transfer difference NMR to verify metabolite binding and regulation of human TET2 dioxygenase. The approach distinguishes functional effects from direct molecular interactions and provides a practical framework for identifying TET2 activators, inhibitors, and candidate metabolism–epigenetics connections.

• IWP-L6: Practical Porcupine Inhibition Workflows

  2026-08-15

  IWP-L6 enables precise upstream control of Wnt ligand production for cell, organ culture, and regeneration studies. This workflow-focused guide connects sub-nanomolar Porcn inhibition with metabolic, developmental, and tissue-patterning assays while emphasizing controls, dosing logic, and troubleshooting.

• 1-methyl Adenosine: From RNA Mark to Biomarker

  2026-08-15

  1-methyl Adenosine is more than a modified nucleoside: it is a measurable endpoint of RNA turnover with implications for RNA modification research, cancer metabolism, and biomarker discovery. This guide explains how analytical design determines what 1-methyl Ado measurements can—and cannot—reveal.

• Trichostatin A in Oncolytic Virus Research

  2026-08-14

  Trichostatin A (TSA) is more than a benchmark HDAC inhibitor: it can reshape tumor-cell permissiveness to oncolytic herpes simplex virus. This article translates mechanistic evidence into practical assay decisions for epigenetic regulation in cancer and combination cancer research.

• CD36 Lipid Signaling Drives Immune Escape in AML

  2026-08-14

  This 2024 Cell Reports Medicine study identifies a non-canonical CD36 lipid-sensing program that enables acute myeloid leukemia cells to suppress T-cell activity and resist decitabine therapy. Its mechanistic model links oxidized LDL, palmitate transfer, TLR4–MYD88–NF-κB signaling, and lipid-lowering statins, providing a rationale for combining metabolic intervention with hypomethylating-agent treatment.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page